Detalhe da pesquisa
1.
Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.
N Engl J Med
; 388(21): 1966-1980, 2023 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37224198
2.
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
Lancet
; 401(10383): 1159-1171, 2023 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36871574
3.
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Gastroenterology
; 165(6): 1443-1457, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37659673
4.
ADC Values for Detecting Bowel Inflammation and Biologic Therapy Response in Patients With Crohn Disease: A Post Hoc Prospective Trial Analysis.
AJR Am J Roentgenol
; 222(1): e2329639, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37584507
5.
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Lancet
; 399(10340): 2031-2046, 2022 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644155
6.
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
Lancet
; 399(10340): 2015-2030, 2022 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644154
7.
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Lancet
; 399(10341): 2113-2128, 2022 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35644166
8.
Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
Gastroenterology
; 162(6): 1650-1664.e8, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35134323
9.
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results.
Gastroenterology
; 162(7): 1876-1890, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35122766
10.
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.
Gastroenterology
; 162(7): 1891-1910, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35227777
11.
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease.
Gastroenterology
; 163(4): 950-964, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35788348
12.
Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis.
Dig Dis Sci
; 68(6): 2318-2332, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36773193
13.
An Expert Consensus to Standardize Assessment of Bowel Cleansing for Clinical Trials of Bowel Preparations for Crohn's Disease.
Dig Dis Sci
; 68(5): 1718-1727, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36436154
14.
Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn's Disease in the CELEST Extension Study.
Clin Gastroenterol Hepatol
; 20(10): 2337-2346.e3, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34968730
15.
Responsiveness of Magnetic Resonance Enterography Indices for Evaluation of Luminal Disease Activity in Crohn's Disease.
Clin Gastroenterol Hepatol
; 20(11): 2598-2606, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35149220
16.
Avoiding contrast-enhanced sequences does not compromise the precision of the simplified MaRIA for the assessment of non-penetrating Crohn's disease activity.
Eur Radiol
; 32(5): 3334-3345, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35031844
17.
Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel (Mesenchymal Stem Cell Treatment) in Patients With Perianal Fistulizing Crohn's Disease: ADMIRE-CD Phase 3 Randomized Controlled Trial.
Dis Colon Rectum
; 65(5): 713-720, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34890373
18.
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
Gastroenterology
; 158(8): 2139-2149.e14, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32092309
19.
Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
Gastroenterology
; 158(3): 550-561, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31711921
20.
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
Gastroenterology
; 158(8): 2123-2138.e8, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32044319